{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-030196","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.275469+00:00","generated_at":"2026-06-22T13:53:26.462678+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Matinas BioPharma reports Q3 net loss of $5.5M; MAT2203 Phase 2 meets primary endpoint with 95% survival","bullets":["Phase 2 EnACT MAT2203 met primary endpoint: 95% 2-week survival; mean EFA 0.30. Overall survival 90% at 18 weeks.","Phase 3 registration trial planned Q1 2023; expects enrollment ~18 months, topline data H2 2024.","Cash $33.1M at Sep 30, 2022 (down from $49.6M); sufficient through 2023. Net loss $5.5M ($0.03/sh) vs $6.8M.","Eric Ende appointed Chairman effective Oct 1, 2022; founding Chairman Conrad remains as independent director.","Recorded $1.1M revenue from BioNTech collaboration; advanced discussions for license option on LNC platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-030196","json":"https://secwatch.observer/filing/0001493152-22-030196.json","markdown":"https://secwatch.observer/filing/0001493152-22-030196.md","text":"https://secwatch.observer/filing/0001493152-22-030196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000149315222030196/0001493152-22-030196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000149315222030196/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T13:53:26.462678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a989bc9b3cfcefa481d769c3b126453806528987","claim":"Matinas BioPharma Holdings, Inc. reported the third quarter ended September 30, 2022 results: revenue $1.1 million, net income $5.5 million, EPS $0.03 per share.","evidence_excerpt":"For the third quarter of 2022, net loss attributable to common shareholders was $5.5 million, or a net loss of $0.03 per share (basic and diluted), compared to a net loss attributable to common shareholders of $6.8 million, or a net loss of $0.03 per share (basic and diluted), for the same period in 2021. The reduced loss resulted from the Company recording $1.1 million in revenue from its research collaboration with BioNTech SE, along with a slight decrease in operating expenses year over year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315222030196/0001493152-22-030196-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$1.1 million"},{"label":"Net income","value":"$5.5 million"},{"label":"EPS","value":"$0.03 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}